Testosterone replacement therapy and prostate health

Current Urology Reports

Volumn 13, Issue 6, 2012, Pages 441-446

  Polackwich, A Scott ^a   Ostrowski, Kevin A ^a   Hedges, Jason C ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Benign prostatic hyperplasia, prostate volume, IPSS; BPH; Lower urinary tract symptoms; LUTS; Prostate; Prostate specific antigen; PSA; Testosterone replacement

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; CHORIONIC GONADOTROPIN; DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE ENANTATE;

ARTICLE; DRUG EFFICACY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; NONHUMAN; ORGANOGENESIS; PROSTATE HYPERTROPHY; PROSTATE VOLUME; RANDOMIZED CONTROLLED TRIAL (TOPIC); TESTOSTERONE BLOOD LEVEL; TESTOSTERONE REPLACEMENT THERAPY; DRUG EFFECT; MALE; PROSTATE;

HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROSTATE; PROSTATIC HYPERPLASIA; TESTOSTERONE;

EID: 84877142291     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0275-8     Document Type: Article

References (33)

1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men. J Clin Endocrinol Metab. 2001;86(2):724-31.
2. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87(2):589-98.
3. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metabol. 2004;89:5920-6.
4. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085-98.
5. •• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7. While not focused on benign disease, this discovery won the Nobel Prize in Medicine and established the link between testosterone and prostate cancer growth.
6. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls Clin. Endocrinol. 1994;40:341-6.
7. Meikle WA, Stephenson RA, Lewis CM. Middleton Effects of age and sex hormones on transition and peripheral zone volumes in benignprostatic hyperplasia in twins J. Clin Endocrinol Metab. 1997;82:571-5.
8. •• Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-75. This recent meta-analysis provides an overview of adverse effects of testosterone replacement therapy.
9. • Nickel JC. Comparison of Clinical Trials With Finasteride and Dutasteride. Rev Urol. 2004;6 Suppl 9:S31-9. This review provides comparison trials of Finasteride and Dutasteride.
10. •• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55(2):310-20. Epub 2008 Sep 24. This paper provides an overview of the Saturation Model of Testosterone and the Prostate.
11. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2008;168(12):1416-24. Epub 2008 Oct 21.
12. Goldenberg SL, Koupparis A, Robinson ME. Differing levels of testosterone and the prostate: a physiological interplay. Nat Rev Urol. 2011;8(7):365-77.
13. •• Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351-61. Well designed RCT that evaluates the effects of Serum testosterone and intraprostatic levels, gene expression and prostate growth.
14. Page ST, Lin DW, Mostaghel EA, et al. Dihydrotestosterone Administration Does Not Increase Intraprostatic Androgen Concentrations or Alter Prostate Androgen Action in Healthy Men: A Randomized -Controlled Trial. J Clin Endocrinol Metab. 2011;96(2):430-7.
15. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003;24(3):299-311.
16. • Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011;186(3):1005-11. Epub 2011 Jul 23. Evaluates the effect of TRT and PSA over a year, and the changes during that year.
17. Coward RM, Simhan J, Carson 3rd CC. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int. 2009;103(9):1179-83. Epub 2008 Dec 23.
18. Rhoden EL, Morgentaler A. influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res. 2006;18:201-5.
19. Chapple CR, Wein AJ, Abrams P, Dmochowski RR, Giuliano F, Kaplan SA, McVary KT, Roehrborn CG. Lower Urinary Tract Symptoms Revisited: A Broader Clinical Perspective. Eur Urol. 2008;54(3):563-9.
20. • Shigehara K, Sugimoto K, Konaka H, et al. Androgen Replacement Therapy Contributes to Improving Lower Urinary Tract Symptoms in Patients with Hypogonadism and Benign Prostate Hypertrophy: a randomized controlled study. Aging Male. 2011;14(1):53-8. RCT examining the relationship between treatment of LOH and LUTS.
21. Favilla V, Cimino S, Castelli T, et al. Relationship Between Lower Urinary Tract Symptoms and Serum Levels of Sex Hormones in Men with Symptomatic Benign Prostatic Hyperplasia. BJUI. 2010;106:1700-3.
22. Liao CH, Chiang HS, Yu HJ. Serum Testosterone Levels Significantly Correlate with Nocturia in Men Aged 40-79 Years. J Urol. 2011;78(3):631-5.
23. Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, Barrett-Connor E. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int. 2010;105(11):1554-9.
24. Takao T, Tsujimura A, Nakayama J, et al. Lower Urinary Tract Symptoms After Hormone Replacement Therapy in Japanese Patients with Late-onset Hypogonadism: A Preliminary Report. Int J Urol. 2009;16:212-4.
25. Haider H, Gooren LJ, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia. 2009;41(1):7-13.
26. Amano T, Imao T, Takemae K, et al. Testosterone Replacement Therapy by Testosterone Ointment Relieves Lower Urinary Tract Symptoms in Late Onset Hypogonadism Patients. Aging Male. 2010;13(4):242-6.
27. • Zhang Y, Chen J, Hu L, et al. Androgen Deprivation Induces Bladder Histological Abnormalities and Dysfunction via TGF-beta in Orchiectomized Mature Rats. Tohoku J Exp Med. 2012;226:121-8. Basic science paper that provides a histological explanation for findings of improvement of LUTS with TRT.
28. • Gacci M, Corona G, Salvi M, et al. A Systematic Review and Meta-Analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with Alpha-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. EAU. 2012;61:994-1003. Recent meta-analysis demonstrating the superiority of dual agent therapy.
29. Kruep EJ, Hogue SL, Eaddy MT, Chandra MD. Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia. P T. 2011;36(8):493-507.
30. Idan A, Griffiths KA, Harwood DT, et al. Long-Term Effects of Dihydrotestosterone Treatment on Prostate Growth in Healthy, Middle-Ages Men Without Prostate Disease. Ann Intern Med. 2010;153:621-32.
31. Marberger M, Roehrborn CG, Marks LS, et al. Relationship among Serum Testosterone, Sexual Function, and the Response to Treatment in Men Receiving Dutasteride for Benign Prostatic Hyperplasia. J Clin Endocrinol Metab. 2006;91(4):1323-8.
32. • Page ST, Hirano L, Gilchriest J, et al. Dutasteride Reduces Prostate Size and Prostate Specific Antigen in Older Hypogonadal Men With Benign Prostatic Hyperplasia Undergoing Testosterone Replacement Therapy. J Urol. 2011;186:191-7. RCT demonstrating TRT does not interfere with the action of 5ARIs.
33. Hong, Sung Kyu. Min, Gyeong Eun. Ha, Seung Bum, et al.: Effect of the dual 5-alpha- reductase inhibitor, dutasteride, on serum testosterone and body mass index in med with benign prostatic hyperplasia. BJUI 2009 105, 970-97.